XML 25 R12.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

Revenue | 3 Months Ended
--- | ---
Mar. 29, 2024
Revenue from Contract with Customer [Abstract] |
Revenue | REVENUE The following tables present the Company’s revenues disaggregated by geographical region and revenue type for the three-month periods ended March 29, 2024 and March 31, 2023 ($ in millions). Sales taxes and other usage-based taxes collected from customers are excluded from revenue.
| Biotechnology |  | Life Sciences |  | Diagnostics |  | Total
For the Three-Month Period Ended March 29, 2024: |  |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |
North America(a) | $ | 514 |  |  | $ | 781 |  |  | $ | 1,337 |  |  | $ | 2,632 |
Western Europe | 546 |  |  | 372 |  |  | 406 |  |  | 1,324 |
Other developed markets(b) | 79 |  |  | 125 |  |  | 99 |  |  | 303 |
High-growth markets(c) | 385 |  |  | 467 |  |  | 685 |  |  | 1,537 |
Total | $ | 1,524 |  |  | $ | 1,745 |  |  | $ | 2,527 |  |  | $ | 5,796 |
Revenue type: |  |  |  |  |  |  |
Recurring | $ | 1,309 |  |  | $ | 1,192 |  |  | $ | 2,294 |  |  | $ | 4,795 |
Nonrecurring | 215 |  |  | 553 |  |  | 233 |  |  | 1,001 |
Total | $ | 1,524 |  |  | $ | 1,745 |  |  | $ | 2,527 |  |  | $ | 5,796 |
For the Three-Month Period Ended March 31, 2023: |  |  |  |  |  |  |
Geographical region: |  |  |  |  |  |  |
North America(a) | $ | 618 |  |  | $ | 708 |  |  | $ | 1,124 |  |  | $ | 2,450 |
Western Europe | 647 |  |  | 364 |  |  | 420 |  |  | 1,431 |
Other developed markets(b) | 79 |  |  | 128 |  |  | 117 |  |  | 324 |
High-growth markets(c) | 520 |  |  | 509 |  |  | 715 |  |  | 1,744 |
Total | $ | 1,864 |  |  | $ | 1,709 |  |  | $ | 2,376 |  |  | $ | 5,949 |
Revenue type: |  |  |  |  |  |  |
Recurring | $ | 1,511 |  |  | $ | 1,039 |  |  | $ | 2,112 |  |  | $ | 4,662 |
Nonrecurring | 353 |  |  | 670 |  |  | 264 |  |  | 1,287 |
Total | $ | 1,864 |  |  | $ | 1,709 |  |  | $ | 2,376 |  |  | $ | 5,949 |
(a) The Company defines North America as the United States and Canada. (b) The Company defines other developed markets as all the markets of the world that are not North America, Western Europe or high-growth markets. (c) The Company defines high-growth markets as developing markets of the world experiencing accelerated growth, over extended periods, in gross domestic product and infrastructure which include Eastern Europe, the Middle East, Africa, Latin America (including Mexico) and Asia (with the exception of Japan, Australia and New Zealand). The Company defines developed markets as all markets of the world that are not high-growth markets. The Company’s products and services primarily consist of life sciences research, biopharmaceutical drug production and medical diagnostic, products and services. The Company sells equipment to customers as well as consumables, software and services, some of which customers purchase on a recurring basis. Consumables sold for use with the equipment sold by the Company are typically critical to the use of the equipment and are typically used on a one-time or limited basis, requiring frequent replacement in the customer’s operating cycle. Examples of these consumables include reagents used in diagnostic tests, chromatography resins used for research and bioprocessing and filters used in filtration, separation and purification processes. Additionally, some of the Company’s consumables are used on a standalone basis, such as custom nucleic acids, genomics solutions, antibodies and immunoassays. The Company separates its goods and services between those typically sold to a customer on a recurring basis and those typically sold to a customer on a nonrecurring basis. Recurring revenue includes revenue from consumables (both used with Company equipment and used on a standalone basis), services and operating-type leases (“OTLs”). Nonrecurring revenue includes sales of equipment and sales-type leases (“STLs”). OTLs and STLs are included in the above revenue amounts. For the three-month periods ended March 29, 2024 and March 31, 2023, lease revenue was $99 million and $101 million, respectively. Remaining performance obligations related to Topic 606, Revenue from Contracts with Customers, represent the aggregate transaction price allocated to performance obligations with an original contract term greater than one year which are fully or partially unsatisfied at the end of the period. As of March 29, 2024, the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $4.6 billion. The Company expects to recognize revenue on approximately 52% of the remaining performance obligations over the next 12 months, 25% over the subsequent 12 months, and the remainder recognized thereafter. The timing of revenue recognition, billings and cash collections results in billed accounts receivable, unbilled receivables (“contract assets”) and deferred revenue, customer deposits and billings in excess of revenue recognized (“contract liabilities”) on the Consolidated Condensed Balance Sheets. Contract assets and liabilities are reported on a net basis on the accompanying Consolidated Condensed Balance Sheets on a contract-by-contract basis at the end of each reporting period. The Company often receives cash payments from customers in advance of the Company’s performance resulting in contract liabilities that are classified as either current or long-term in the Consolidated Condensed Balance Sheets based on the timing of when the Company expects to recognize revenue. As of March 29, 2024 and December 31, 2023, contract liabilities were approximately $1.8 billion and $1.7 billion, respectively, and are included within accrued expenses and other liabilities and other long-term liabilities in the accompanying Consolidated Condensed Balance Sheets. The increase in the contract liability balance during the three-month period ended March 29, 2024 was primarily a result of cash payments received in advance of satisfying performance obligations, partially offset by amounts recognized as revenue. Revenue recognized during the three-month periods ended March 29, 2024 and March 31, 2023 that was included in the contract liability balance on December 31, 2023 and December 31, 2022 was approximately $547 million and $596 million, respectively.

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-9 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-15 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org//606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration